Celgene’s Pomalyst (pomalidomide)-Based Triple Regimen Receive Health Canada’s Approval for Multiple Myeloma

Celgene’s Pomalyst (pomalidomide)-Based Triple Regimen Receive Health Canada’s Approval for Multiple Myeloma

Shots:

  • The approval is based on P-III OPTIMISMM study results assessing Pomalyst + bortezomib and dexamethasone vs bortezomib + dexamethasone in 559 patients in a ratio (1:1) with 2L+ MM and prior treated with/or refractory to Revlimid (lenalidomide)
  • The P-III OPTIMISMM study results: mPFS (11.2 mos. vs 7.1 mos.), reduction in diseases progression by 39%, patients with 1L therapy, mPFS (20.73 mos. vs 11.63mos.)
  • Pomalyst is an immunomodulatory therapy act by enhancing T-cell & NK-cell mediated immunity, indicated to treat MM as triple regimen therapy with Takeda’s Velcade (bortezomib) and dexamethasone

Click here to read full press release/ article | Ref: Canada Newswire | Image: QUAPE